Discover
PHVS
Pharvaris N.V.
34.45
1 x 33.76
1 x 35.13
bid
ask
+
0.90
2.68%
1 @ 04:00 PM
34.44 -0.01 (0.03%)
| Ytd | 24.14% | |
| 1y | 44.51% |
33.01
day range
34.67
11.51
52 week range
36.90
| Open | 34.17 | Prev Close | 33.55 | Low | 33.01 | High | 34.67 | Mkt Cap | 2.29B |
| Vol | 268.57K | Avg Vol | 560.46K | EPS | -3.18 | P/E | N/A | Forward P/E | -13.07 |
| Beta | -2.34 | Short Ratio | 2.39 | Inst. Own | 85.30% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 32.20 | 200-d Avg | 27.53 | 1yr Est | 47.27 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-11 | 2026-06 | -0.74 | N/A | N/A | N/A |
| 2026-05-12 | 2026-03 | -0.82 | -0.7 | 0.12 | 14.83% |
| 2026-04-02 | 2025-12 | -0.71 | -0.85 | -0.13 | -18.34% |
| 2025-11-12 | 2025-09 | -0.78 | -0.7 | 0.08 | 10.26% |
| 2025-08-12 | 2025-06 | -0.87 | -0.94 | -0.07 | -8.05% |
| 2025-05-13 | 2024-12 | -0.8 | -0.89 | -0.09 | -11.25% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-25 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-05-13 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2026-04-09 | Wolfe Research | Upgrade | Outperform | |
| 2026-04-07 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-04-06 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-03-09 | RBC Capital | Upgrade | Outperform |
Profile
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-05-14 | ABELE STEFAN | Chief Operating Officer | 35.19K | Sale |
| 2026-05-19 | BJORK ELISABETH | Director | 15.17K | Sale |
| 2026-05-14 | GLASSMAN ROBERT R. | Director | 10.50K | Sale |
| 2026-06-29 | LESAGE ANNE SIMONNE J PH.D. | Officer | 0.00 | Sale |
| 2026-06-25 | LU PENG | Officer | 65.63K | Sale |
| 2026-06-14 | MODIG BERNDT B.A.E | Chief Executive Officer | 1.09M | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | General Atlantic Llc | 8.03M | 0.00 | 11.49% |
| 2026-03-30 | FMR Inc | 6.28M | 0.00 | 8.99% |
| 2026-03-30 | Foresite Capital Management IV, LLC | 4.78M | 0.00 | 6.84% |
| 2026-03-30 | venBio Partners LLC | 4.64M | 0.00 | 6.64% |
| 2026-03-30 | Viking Global Investors LP | 3.65M | 0.00 | 5.23% |
| 2026-03-30 | EQT Fund Management S.à r.l. | 3.42M | 0.00 | 4.90% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | Fidelity Growth Compy Commingled Pl S | 1.91M | 0.00 | 2.74% |
| 2026-05-30 | Fidelity Growth Company Fund | 1.37M | 0.00 | 1.97% |
| 2026-05-30 | Fidelity Select Health Care | 800.00K | 0.00 | 1.14% |
| 2026-05-30 | Polar Capital Biotech S Inc | 761.73K | 0.00 | 1.09% |
| 2026-04-29 | Fidelity Small Cap Growth | 644.59K | 0.00 | 0.92% |
| 2026-05-30 | Fidelity Advisor Health Care I | 500.00K | 0.00 | 0.72% |